Astrazeneca Plc $AZN Shares Bought by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc increased its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 9.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,787 shares of the company’s stock after purchasing an additional 3,337 shares during the period. Marks Group Wealth Management Inc’s holdings in Astrazeneca were worth $6,632,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Lloyd Advisory Services LLC. acquired a new position in Astrazeneca in the fourth quarter valued at $35,000. Basepoint Wealth LLC acquired a new position in Astrazeneca in the fourth quarter valued at $44,000. Nemes Rush Group LLC increased its stake in Astrazeneca by 162.1% in the fourth quarter. Nemes Rush Group LLC now owns 270 shares of the company’s stock valued at $47,000 after purchasing an additional 167 shares during the period. Bangor Savings Bank increased its stake in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the period. Finally, Eagle Bay Advisors LLC acquired a new position in Astrazeneca in the fourth quarter valued at $30,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Weiss Ratings assumed coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Finally, DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Down 2.2%

Shares of NYSE:AZN opened at $181.81 on Tuesday. The company has a market cap of $281.97 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 1.59 and a beta of 0.25. The firm’s 50-day simple moving average is $190.70 and its 200-day simple moving average is $185.53. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71.

Astrazeneca (NYSE:AZN) last issued its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, equities research analysts predict that Astrazeneca Plc will post 9.52 earnings per share for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.